November 2024

SAN DIEGO, Nov. 4, 2024 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the long-term KINECT®-4 study demonstrating tardive dyskinesia remission in nearly 60% of participants at Week 48 with once-daily INGREZZA® (valbenazine) capsules treatment. This research,

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: